Connectome Raises $2M for Brain Health Monitoring

A new player in the rapidly expanding neurotechnology sector, Connectome, has successfully closed a $2 million pre-seed funding round. This capital infusion is earmarked to accelerate the development of its innovative platform designed for continuous, personalized brain health monitoring. The round was spearheaded by Redstone, with significant backing from Concept Ventures and Octopus Ventures, alongside a cohort of European and US-based angel and strategic investors. The company also bolstered its financial position with an additional $120,000 in non-dilutive public funding, underscoring strong early-stage validation.

Founded in 2024 by neuroscientist Lucas Scherdel, who brings a personal understanding of neurological challenges, Connectome is pioneering a novel approach to cognitive well-being. The platform aims to move beyond the limitations of infrequent, snapshot assessments. By integrating real-time brain activity data with contextual information such as sleep patterns, physical exertion, and daily cognitive load, Connectome seeks to build a dynamic, individualized profile of brain function.

The core innovation lies in its methodology of frequent, long-term monitoring to establish robust personal baselines. This contrasts sharply with traditional neurological evaluations that often capture a single point in time. By meticulously tracking subtle deviations from an individual's norm, Connectome's technology is positioned to identify early indicators of a spectrum of conditions, from professional burnout and attention deficit hyperactivity disorder (ADHD) to the nascent stages of neurodegenerative diseases like dementia. This approach is grounded in extensive research, including work conducted with Imperial College London, which demonstrated that everyday life leaves a discernible, quantifiable imprint on brain activity.

“The critical role of cognitive health in our professional lives, social interactions, and aging process is undeniable, yet its measurement remains remarkably rudimentary,” stated Lucas Scherdel, CEO of Connectome. He articulated the company’s mission to bridge the significant disparity between the advanced monitoring capabilities available for physical health and the comparatively underdeveloped tools for assessing brain health. The company envisions a future where proactive brain health management is as accessible as tracking heart rate or daily steps.

The newly acquired capital will be strategically deployed to advance the platform's technological capabilities, facilitate initial product deployments with key strategic partners, and expand its research initiatives, including further validation of the LUCIID study findings. Connectome has ambitious plans to extend its platform's utility beyond consumer wearables and lifestyle applications, targeting significant clinical and enterprise markets. This dual focus suggests a strategy to build both a direct-to-consumer offering and a robust B2B solution for healthcare providers and corporations.

With operations spanning Zurich and London, Connectome benefits from a unique blend of Swiss engineering precision and leading UK neuroscience expertise. This pre-seed funding round provides a solid foundation for Connectome to launch its initial product offerings and solidify its research pipeline, positioning it as a noteworthy contender in the burgeoning digital health and neurotech industries. The market for cognitive health solutions is experiencing significant growth, driven by an aging global population and increasing awareness of mental well-being, creating a fertile ground for innovations like Connectome's.